Inappropriate antidiuretic hormone secretion after high-dose thiotepa

Bone Marrow Transplantation

Volumn 24, Issue 5, 1999, Pages 571-572

  Sica, S ^a   Cicconi, S ^a   Sora F ^a   Chiusolo, P ^a   Piccirillo, N ^a   Laurenti, L ^a   Ortu La Barbera, E ^a   Giordano, G ^a   Leone, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Autologous stem cell transplantation; SIADH; Thiotepa

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; PHENYTOIN; THIOTEPA;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CONDITIONING; DRUG MEGADOSE; FEMALE; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER TOXICITY; LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEIZURE; STEM CELL TRANSPLANTATION;

EID: 0032879810     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701922     Document Type: Article

References (3)

1. Jones RB, Matthes S, Dufton C. Pharmacokinetics. In: Armitage JO, Antman KH (eds). High-dose Cancer Therapy. Williams & Wilkins: Baltimore, 1995, pp 49-68.
2. Przepiorka D, Dimopoulos M, Smith T et al. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol 1994; 68: 183-188.
3. Kleta R, Wagner A, Jurgens H. Recurrence of SIADH after high-dose regimen of thiotepa, carboplatin and etoposide phosphate. Med Pediatr Oncol 1998; 31: 129.